Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2024; . Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?
by JM LaForge 2024 Cited by 18Similar Articles. Non-steroidal Anti-inflammatory Drugs: Clinical Implications, Renal Impairment Risks, and AKI. LaForge JM 1 . Urso K 2 . Day JM 3 .
by JM Weaver 2024Good drugs and bad drugs: what's the difference? JM Weaver Copyright and License information PMC Disclaimer
JM De Guzman recalls his drug relapse in 2024: 'I was imprisoned by pain and hate'
by JM Morales 2024 Cited by 67immunosuppressive drugs such as corticosteroids and for graft failure. Immunosuppressive drugs such as corticoste- roids, cyclosporine and tacrolimus may be
by JM Kane 2024 Cited by 3482. Davis JM, Schaffer CB, Killian GA, et al: Important issues in the drug treatment of schizophrenia . Schizophr Bull 2024;6: .Crossref.
hydrochlorothiazide and chlorothiazide bendroflumethiazide methyclothiazide Wright JM (ed.). First-line drugs for hypertension. The Cochrane
Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2024; . Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?
Topics: prescription drugs, healthcare, India, drug prices, regulations. The JM Buzz Podcast is a production of the American Marketing Association's Journal
See contract arrangements in Chapter 8.
JM